Research Papers

25 of 83 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Direct oral anticoagulant use in hospitalized patients with atrial fibrillation across body mass index categories: desi…
Shaikh F; Wynne R; L Castelino R; Inglis SC; Davidson PM; Ferguson C.
Ther Adv Drug Saf (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System …
Jiang T; Su H; Xu J; Li C; Zhang N; Li Y; Wu Y; Ni R; Ming Y; Li Z; Li L; Liu Y.
Ther Adv Drug Saf (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Evaluation of four machine learning models for signal detection.
Dauner DG; Leal E; Adam TJ; Zhang R; Farley JF.
Ther Adv Drug Saf (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: …
Fitsum Y; Werede A; Mahmud Saleh A; Tesfamariam EH; Magombo F; Misghina F; Yemane H; Bahta I; Abraham L; Bahta M; Debesai M; Tesfagaber M; Ghirmai M; Tesfamariam S; Russom M.
Ther Adv Drug Saf (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Acceptability of a cross-sectoral hospital pharmacist intervention for patients in transition between hospital and gene…
Sørensen CA; Jeffery L; Roelsgaard K; Gram S; Falhof J; Harbig P; Olesen C.
Ther Adv Drug Saf (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Funding and financial sustainability of pharmacovigilance: suggested models for funding pharmacovigilance in resource-l…
Isah AO; Opadeyi AO; Tumwijukye H; Cobelens F; Smith D; Ndomondo-Sigonda M; Harmark L; Tanui P; Tiemersma E; Mmbaga BT; Mahlangu G; Ayinbuomwan SA; Soulaymani R; Pandit JM.
Ther Adv Drug Saf (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Flow rate accuracy of infusion devices within healthcare settings: a systematic review.
Atanda O; West J; Stables T; Johnson C; Merrifield R; Kinross J.
Ther Adv Drug Saf (Unknown)
Published: 2023
5/6 Transparent
Data Registered Funding Declared
Safety monitoring of oral iron supplements in pregnant women with anemia: a multi-center observational clinical study.
Liu C; Zhang Q; Hui P; Wang Y; Li G; Cao G; Xue Z; Zhang J; Zhang H; Huang X; Wu J; Sun F; Yan M.
Ther Adv Drug Saf (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Survival outcomes of beta-blocker usage in HER2-positive advanced breast cancer patients: a retrospective cohort study.
Hsieh HH; Wu TY; Chen CH; Kuo YH; Hour MJ.
Ther Adv Drug Saf (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors <i>versus</i> DPP4 inhibitors or GLP-1 agonis…
Lu Y; Guo C.
Ther Adv Drug Saf (Unknown)
Published: 2023
4/6 Transparent
Registered Funding Declared
Therapy of women with multiple sclerosis: an analysis of the use of drugs that may have adverse effects on the unborn c…
Haker MC; Frahm N; Hecker M; Langhorst SE; Mashhadiakbar P; Debus JL; Streckenbach B; Baldt J; Heidler F; Zettl UK.
Ther Adv Drug Saf (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Analysis of the nature and contributory factors of medication safety incidents following hospital discharge using Natio…
Alqenae FA; Steinke D; Carson-Stevens A; Keers RN.
Ther Adv Drug Saf (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Developing and piloting a cross-sectoral hospital pharmacist intervention for patients in transition between hospital a…
Sørensen CA; Jeffery L; Falhof J; Harbig P; Roelsgaard K; Gram S; Olesen C.
Ther Adv Drug Saf (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse eve…
Altebainawi AF; Alfaraj LA; Alharbi AA; Alkhuraisi FF; Alshammari TM.
Ther Adv Drug Saf (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Patient-centered pharmacovigilance: priority actions from the inherited bleeding disorders community.
Robinson F; Wilkes S; Schaefer N; Goldstein M; Rice M; Gray J; Meyers S; Valentino LA.
Ther Adv Drug Saf (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
A survey on self-medication for the prevention or treatment of COVID-19 and distrust in healthcare of veterans in a pri…
Amenta E; Grigoryan L; Dillon L; Hines-Munson C; Van J; Trautner B.
Ther Adv Drug Saf (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study.
Nordstrom BL; Cai B; De Gregorio F; Ban L; Fraeman KH; Yoshida Y; Gibbs T.
Ther Adv Drug Saf (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cancer risk: an updated meta-analysis of …
Shin K; Yang J; Yu Y; Son E; Kim K; Kim YH.
Ther Adv Drug Saf (Unknown)
Published: 2022
4/6 Transparent
Registered Funding Declared
Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases.
Shen K; Gu Y; Wang Y; Lu Y; Ni Y; Zhong H; Shi Y; Su X.
Ther Adv Drug Saf (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Increasing patient involvement through self-administration of medication.
Khaja S.
Ther Adv Drug Saf (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Development of a deprescribing manual for frail older people for use in the COFRAIL study and in primary care.
Mann NK; Schmiedl S; Mortsiefer A; Bencheva V; Löscher S; Ritzke M; Drewelow E; Feldmeier G; Santos S; Wilm S; Thürmann PA; COFRAIL study group.
Ther Adv Drug Saf (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge.
Rudolph A; Mitchell J; Barrett J; Sköld H; Taavola H; Erlanson N; Melgarejo-González C; Yue QY.
Ther Adv Drug Saf (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Prevalence and global trends of polypharmacy among people living with HIV: a systematic review and meta-analysis.
Danjuma MI; Adegboye OA; Aboughalia A; Soliman N; Almishal R; Abdul H; Mohamed MFH; Elshafie MN; AlKhal A; Elzouki A; Al-Saud A; Chaponda M; Bidmos MA.
Ther Adv Drug Saf (Unknown)
Published: 2022
4/6 Transparent
Registered Funding Declared
Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingre…
Clark NF; Taylor-Robinson AW; Heimann K.
Ther Adv Drug Saf (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
The patterns and implications of potentially suboptimal medicine regimens among older adults: a narrative review.
Lee GB; Etherton-Beer C; Hosking SM; Pasco JA; Page AT.
Ther Adv Drug Saf (Unknown)
Published: 2022
3/6 Transparent
Funding Declared